ZTI BIOSCIENCES specializes in the development of radiopharmaceuticals for cancer therapeutics based on the Nano-tech platform (TERACARRIER™), distinguished as the world's first and only technology. [Business Model] BM1) Validating TERACARRIER™ technology through FDA Licensing strategy. BM2) Licensing out to global pharmaceutical companies and expanding pipeline based on the TERACARRIER™ platform. BM3) Launching a radiopharmaceutical CDMO business based on TERACARRIER™. [Pipeline] ZTI-101 utilizes 177Lu for orphan disease (ovarian cancer), targeting IND approval this year. ZTI-201 is using 225Ac, which has strong therapeutic activity, overcoming the technically challenging delivery of high-energy alpha daughters through TERACARRIER™ technology. TERACARRIER™'s versatile platform extends to the new targeting agent applied pipeline, designed for solid tumor treatment using from small molecule to antibody.